$1,318.00
This Market Spotlight report covers the Endometriosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Endometriosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
8 TREATMENT
8 GnRH analogs
8 Progestins
8 Combined oral contraceptives
8 Non-steroidal anti-inflammatory drugs
8 Danocrine
9 Surgery
10 EPIDEMIOLOGY
13 MARKETED DRUGS
16 PIPELINE DRUGS
21 RECENT EVENTS AND ANALYST OPINION
21 Yselty for Endometriosis (January 6, 2022)
23 Orgovyx for Endometriosis (January 26, 2021)
25 KEY UPCOMING EVENTS
26 PROBABILITY OF SUCCESS
27 LICENSING AND ASSET ACQUISITION DEALS
27 Xbrane Pauses Primm Divestment Process
27 Organon Continues Building Women’s Health Portfolio With Forendo Buyout
28 REVENUE OPPORTUNITY
30 CLINICAL TRIAL LANDSCAPE
31 Sponsors by status
32 Sponsors by phase
34 BIBLIOGRAPHY
35 APPENDIX
LIST OF FIGURES
12 Figure 1: Trends in prevalent cases of diagnosed endometriosis, 2021–30
16 Figure 2: Overview of pipeline drugs for endometriosis in the US
16 Figure 3: Pipeline drugs for endometriosis, by company
17 Figure 4: Pipeline drugs for endometriosis, by drug type
17 Figure 5: Pipeline drugs for endometriosis, by classification
23 Figure 6: Yselty for Endometriosis (January 6, 2022): Phase III – EDELWEISS 3 (U.S./Europe)
25 Figure 7: Key upcoming events in endometriosis
26 Figure 8: Probability of success in the gynecology pipeline
30 Figure 9: Clinical trials in endometriosis
30 Figure 10: Top 10 drugs for clinical trials in endometriosis
31 Figure 11: Top 10 companies for clinical trials in endometriosis
31 Figure 12: Trial locations in endometriosis
32 Figure 13: Endometriosis trials status
33 Figure 14: Endometriosis trials sponsors, by phase
LIST OF TABLES
11 Table 1: Prevalent cases of diagnosed endometriosis, 2021–30
14 Table 2: Marketed drugs for endometriosis
18 Table 3: Pipeline drugs for endometriosis in the US
21 Table 4: Yselty for Endometriosis (January 6, 2022)
24 Table 5: Orgovyx for Endometriosis (January 26, 2021)
28 Table 6: Historical global sales, by drug ($m), 2016–20
29 Table 7: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!